Hypothalamic mTOR: The rookie energy sensor

Current Molecular Medicine

Volumn 14, Issue 1, 2014, Pages 3-21

  Martinez de Morentin P B ^a,b   Martinez Sanchez N ^a,b   Roa, J ^b,c,d   Ferno J ^e   Nogueiras, R ^a,b   Tena Sempere, M ^b,c,d   Dieguez C ^a   Lopez M ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF BERGEN   (Norway)

Author keywords

AMPK; Energy balance; Energy expenditure; Food intake; Hypothalamus; mTOR

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; KISSPEPTIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROPEPTIDE; OSTEOGENIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; GHRELIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B;

APOPTOSIS; AUTOPHAGY; ENDOPLASMIC RETICULUM STRESS; ENERGY; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPERPHAGIA; HYPOTHALAMUS; HYPOXIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PUBERTY; REVIEW; SIGNAL TRANSDUCTION; THERMOGENESIS; ADIPOGENESIS; AGING; ARTICLE; BODY WEIGHT; CELL ENERGY; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; INSULIN RESISTANCE; LIPOGENESIS; NEOPLASM; PANCREAS ISLET BETA CELL;

ANIMALS; ENERGY METABOLISM; HORMONES; HUMANS; HYPOTHALAMUS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; PUBERTY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84891883979     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524013666131118103706     Document Type: Review

References (277)

1. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
2. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994; 91: 12574-8.
3. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43.
4. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815-22.
5. Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006; 312: 927-30.
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
7. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008; 8: 224-36.
8. Weichhart T, Saemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 2008; 67 Suppl 3: iii70-iii74.
9. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
10. Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9: 2655-61.
11. Harper JM, Wang M, Galecki AT, Ro J, Williams JB, Miller RA. Fibroblasts from long-lived bird species are resistant to multiple forms of stress. J Exp Biol 2011; 214: 1902-10.
12. Appenzeller-Herzog C, Hall MN. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol 2012; 22: 274-82.
13. Wang Z, Zhong J, Gao D, Inuzuka H, Liu P, Wei W. DEPTOR Ubiquitination and Destruction by SCFbeta-TrCP. Am J Physiol Endocrinol Metab 2012; 303: E163-E169.
14. Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol Biol 2012; 821: 1-14.
15. Thomas HE, Mercer CA, Carnevalli LS, et al. mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. Sci Transl Med 2012; 20: 139ra84.
16. Zou M, Lu N, Hu C, et al. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: Implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling. Cell Signal 2012; 24: 1722-32.
17. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457-68.
18. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-5.
19. Kapahi P, Chen D, Rogers AN, et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11: 453-65.
20. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29: 3733-44.
21. Ropelle ER, Pauli JR, Fernandes MF, et al. A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein dietinduced weight loss. Diabetes 2008; 57: 594-605.
22. Ropelle ER, Fernandes MF, Flores MB, et al. Central exercise action increases the AMPK and mTOR response to leptin. PLoS One 2008; 3: e3856.
23. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012; 52: 381-400.
24. Varela L, Martinez-Sanchez N, Gallego R, et al. Hypothalamic mTOR pathway mediates thyroid hormoneinduced hyperphagia in hyperthyroidism. J Pathol 2012; 227: 209-22.
25. Martins L, Fernandez-Mallo D, Novelle MG, et al. Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS One 2012; 7: e46923.
26. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253: 905-9.
27. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993; 73: 585-96.
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
29. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727-32.
30. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6.
31. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-42.
32. Yonezawa K. Identification of TOR-interacting proteins. Mol Interv 2003; 3: 189-93.
33. Garcia-Echeverria C. Blocking the mTOR pathway: a drug discovery perspective. Biochem Soc Trans 2011; 39: 451-5.
34. Laplante M, Sabatini DM. mTOR Signaling in Growth Control and Disease. Cell 2012; 149: 274-93.
35. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010; 3: 374-91.
36. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011; 4: 476-95.
37. Lopez-Bonet E, Vazquez-Martin A, Perez-Martinez MC, et al. Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PPmTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. Int J Oncol 2010; 36: 107-15.
38. Soliman GA, Acosta-Jaquez HA, Dunlop EA, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2010; 285: 7866-79.
39. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC, Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1998; 95: 7772-7.
40. Reynolds TH, Bodine SC, Lawrence JC, Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002; 277: 17657-62.
41. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010; 33: 67-75.
42. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-26.
43. Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J Biol Chem 2006; 281: 28605-14.
44. Knutson BA. Insights into the domain and repeat architecture of target of rapamycin. J Struct Biol 2010; 170: 354-63.
45. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-22.
46. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48.
47. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
48. Wang L, Rhodes CJ, Lawrence JC, Jr. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J Biol Chem 2006; 281: 24293-303.
49. Zhang Y, Billington CJ, Jr., Pan D, Neufeld TP. Drosophila target of rapamycin kinase functions as a multimer. Genetics 2006; 172: 355-62.
50. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010; 38: 768-74.
51. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-89.
52. Wang C, Mao X, Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 2007; 282: 7991-6.
53. Oshiro N, Takahashi R, Yoshino K, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007; 282: 20329-39.
54. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 2011; 44: 304-16.
55. Kim DH, Sarbassov DD, Ali SM, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003; 11: 895-904.
56. Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol 2006; 16: 958-70.
57. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
58. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
59. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006; 20: 2820-32.
60. Pearce LR, Huang X, Boudeau J, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007; 405: 513-22.
61. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-37.
62. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-84.
63. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122: 3589-94.
64. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 2009; 284: 8023-32.
65. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 1996; 7: 25-42.
66. Shor B, Zhang WG, Toral-Barza L, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68: 2934-43.
67. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
68. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycinsensitive signaling and translation initiation. Proc Natl Acad Sci U S A 2000; 97: 14340-5.
69. Garelick MG, Kennedy BK. TOR on the brain. Exp Gerontol 2011; 46: 155-63.
70. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-57.
71. Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-501.
72. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPaseactivating protein complex toward Rheb. Curr Biol 2003; 13: 1259-68.
73. Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: 1457-66.
74. Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med 2005; 7: 287-96.
75. Ghosh S, Tergaonkar V, Rothlin CV, et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 2006; 10: 215-26.
76. Lee CH, Inoki K, Karbowniczek M, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J 2007; 26: 4812-23.
77. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-6.
78. Ozcan U, Ozcan L, Yilmaz E, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008; 29: 541-51.
79. Camacho A, Rodriguez-Cuenca S, Blount M, et al. Ablation of PGC1 beta prevents mTOR dependent endoplasmic reticulum stress response. Exp Neurol 2012; 237: 396-406.
80. Kahn BB, Myers MG, Jr. mTOR tells the brain that the body is hungry. Nat Med 2006; 12: 615-7.
81. Flier JS. Neuroscience. Regulating energy balance: the substrate strikes back. Science 2006; 312: 861-4.
82. Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 2010; 11: 409-24.
83. Juhasz G, Hill JH, Yan Y, et al. The class III PI(3)K Vps34 promotes autophagy and endocytosis but not TOR signaling in Drosophila. J Cell Biol 2008; 181: 655-66.
84. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005; 25: 5834-45.
85. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294: 1102-5.
86. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-90.
87. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-26.
88. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6: 91-9.
89. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPasedependent manner. Cell Metab 2010; 11: 390-401.
90. Zheng M, Wang YH, Wu XN, et al. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energydepletion-induced suppression of mTORC1. Nat Cell Biol 2011; 13: 263-72.
91. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell 2011; 144: 757-68.
92. Mayer C, Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006; 25: 6384-91.
93. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab 2011; 22: 94-102.
94. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012; 441: 1-21.
95. Banerjee P, Ahmad MF, Grove JR, Kozlosky C, Price DJ, Avruch J. Molecular structure of a major insulin/mitogenactivated 70-kDa S6 protein kinase. Proc Natl Acad Sci U S A 1990; 87: 8550-4.
96. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 1998; 17: 6649-59.
97. Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N, Blenis J. Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene 1999; 18: 5108-14.
98. Pende M, Um SH, Mieulet V, et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogenactivated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 2004; 24: 3112-24.
99. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004; 24: 6710-8.
100. Gangloff YG, Mueller M, Dann SG, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004; 24: 9508-16.
101. Richardson CJ, Broenstrup M, Fingar DC, et al. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 2004; 14: 1540-9.
102. Ma XM, Yoon SO, Richardson CJ, Julich K, Blenis J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 2008; 133: 303-13.
103. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16: 3693-704.
104. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 2001; 20: 4370-9.
105. Tang H, Hornstein E, Stolovich M, et al. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol 2001; 21: 8671-83.
106. Stolovich M, Tang H, Hornstein E, et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol 2002; 22: 8101-13.
107. Patursky-Polischuk I, Stolovich-Rain M, Hausner-Hanochi M, et al. The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor-or rictor-independent manner. Mol Cell Biol 2009; 29: 640-9.
108. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. Science 2006; 314: 467-71.
109. Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008; 283: 8601-10.
110. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003; 23: 26-37.
111. Vornlocher HP, Hanachi P, Ribeiro S, Hershey JW. A 110-kilodalton subunit of translation initiation factor eIF3 and an associated 135-kilodalton protein are encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes. J Biol Chem 1999; 274: 16802-12.
112. Raught B, Peiretti F, Gingras AC, et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 2004; 23: 1761-9.
113. Lejeune F, Maquat LE. Mechanistic links between nonsensemediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 2005; 17: 309-15.
114. Pause A, Methot N, Svitkin Y, Merrick WC, Sonenberg N. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in capdependent and cap-independent initiation of translation. EMBO J 1994; 13: 1205-15.
115. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-18.
116. Mayer C, Zhao J, Yuan X, Grummt I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 2004; 18: 423-34.
117. Marshall L, Rideout EJ, Grewal SS. Nutrient/TOR-dependent regulation of RNA polymerase III controls tissue and organismal growth in Drosophila. EMBO J 2012; 31: 1916-30.
118. Kantidakis T, Ramsbottom BA, Birch JL, Dowding SN, White RJ. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci U S A 2010; 107: 11823-8.
119. Shor B, Wu J, Shakey Q, et al. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 2010; 285: 15380-92.
120. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012; 16: 1203-14.
121. Wu X, Reiter CE, Antonetti DA, Kimball SR, Jefferson LS, Gardner TW. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J Biol Chem 2004; 279: 9167-75.
122. Shang YC, Chong ZZ, Wang S, Maiese K. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and BclxL. Aging (Albany NY) 2012; 4: 187-201.
123. Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007; 19: 263-72.
124. Jung CH, Jun CB, Ro SH, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
125. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-95.
126. Jung CH, Seo M, Otto NM, Kim DH. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. Autophagy 2011; 7: 1212-21.
127. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 2009; 5: 973-9.
128. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13: 132-41.
129. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009; 19: R1046-R1052.
130. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39: 171-83.
131. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010; 107: 3441-6.
132. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A 2011; 108: 15201-6.
133. Koh YK, Lee MY, Kim JW, et al. Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma 2. J Biol Chem 2008; 283: 34896-906.
134. Le BO, Petroulakis E, Paglialunga S, et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007; 117: 387-96.
135. Huffman TA, Mothe-Satney I, Lawrence JC, Jr. Insulinstimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A 2002; 99: 1047-52.
136. Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146: 408-20.
137. Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 2000; 8: 249-54.
138. Gagnon A, Lau S, Sorisky A. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J Cell Physiol 2001; 189: 14-22.
139. Cho HJ, Park J, Lee HW, Lee YS, Kim JB. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 2004; 321: 942-8.
140. Kim JE, Chen J. regulation of peroxisome proliferatoractivated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004; 53: 2748-56.
141. Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 2008; 8: 399-410.
142. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 2005; 307: 1098-101.
143. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74.
144. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-9.
145. Su B, Jacinto E. Mammalian TOR signaling to the AGC kinases. Crit Rev Biochem Mol Biol 2011; 46: 527-47.
146. Calnan DR, Brunet A. The FoxO code. Oncogene 2008; 27: 2276-88.
147. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008; 416: 375-85.
148. Lyo D, Xu L, Foster DA. Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway. Biochem Biophys Res Commun 2010; 396: 562-5.
149. Lu M, Wang J, Ives HE, Pearce D. mSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel. J Biol Chem 2011; 286: 30647-54.
150. Lang F, Artunc F, Vallon V. The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr Opin Nephrol Hypertens 2009; 18: 439-48.
151. Lang F, Strutz-Seebohm N, Seebohm G, Lang UE. Significance of SGK1 in the regulation of neuronal function. J Physiol 2010; 588: 3349-54.
152. Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ. mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J 2011; 439: 287-97.
153. World Health Organization Media Centre: Obesityand overweight. 2012.
154. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
155. Farooqi IS. Monogenic human obesity syndromes. Prog Brain Res 2006; 153: 119-25.
156. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 2009; 462: 307-14.
157. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7: 1003-15.
158. Cheung WW, Mao P. Recent advances in obesity: genetics and beyond. ISRN Endocrinol 2012; 2012: 536905.
159. Karnik S, Kanekar A. Childhood obesity: a global public health crisis. Int J Prev Med 2012; 3: 1-7.
160. Matusitz J, McCormick J. Sedentarism: the effects of internet use on human obesity in the United States. Soc Work Public Health 2012; 27: 250-69.
161. Bean MK, Stewart K, Olbrisch ME. Obesity in America: implications for clinical and health psychologists. J Clin Psychol Med Settings 2008; 15: 214-24.
162. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-9.
163. Mori H, Inoki K, Munzberg H, et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab 2009; 9: 362-74.
164. Shimizu H, Arima H, Ozawa Y, et al. Glucocorticoids increase NPY gene expression in the arcuate nucleus by inhibiting mTOR signaling in rat hypothalamic organotypic cultures. Peptides 2010; 31: 145-9.
165. Stevanovic D, Janjetovic K, Misirkic M, et al. Intracerebroventricular Administration of Metformin Inhibits Ghrelin-Induced Hypothalamic AMP-Kinase Signalling and Food Intake. Neuroendocrinology 2012; 96: 24-31.
166. Roh C, Han J, Tzatsos A, Kandror KV. Nutrient-sensing mTOR-mediated pathway regulates leptin production in isolated rat adipocytes. Am J Physiol Endocrinol Metab 2003; 284: E322-E330.
167. Vander HE, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9: 316-23.
168. Woods AJ, Stock MJ. Leptin activation in hypothalamus. Nature 1996; 381: 745.
169. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology 1997; 138: 839-42.
170. Flier JS, Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998; 92: 437-40.
171. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
172. Elmquist JK. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Int J Obes Relat Metab Disord 2001; 25 Suppl 5: S78-S82.
173. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428: 569-74.
174. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB. Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 2005; 493: 63-71.
175. Lopez M, Lelliott CJ, Vidal-Puig A. Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays 2007; 29: 248-61.
176. Gao Q, Horvath TL. Neurobiology of feeding and energy expenditure. Annu Rev Neurosci 2007; 30: 367-98.
177. Lopez M, Tovar S, Vazquez MJ, Williams LM, Dieguez C. Peripheral tissue-brain interactions in the regulation of food intake. Proc Nutr Soc 2007; 66: 131-55.
178. Martinez de Morentin PB, Whittle AJ, Ferno J, et al. Nicotine Induces Negative Energy Balance Through Hypothalamic AMP-Activated Protein Kinase. Diabetes 2012; 61: 807-17.
179. Whittle AJ, Carobbio S, Martins L, et al. BMP8B Increases Brown Adipose Tissue Thermogenesis through Both Central and Peripheral Actions. Cell 2012; 149: 871-85.
180. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2-40.
181. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-95.
182. Hill JW, Elmquist JK, Elias CF. Hypothalamic pathways linking energy balance and reproduction. Am J Physiol Endocrinol Metab 2008; 294: E827-E832.
183. Roa J, Garcia-Galiano D, Varela L, et al. The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. Endocrinology 2009; 150: 5016-26.
184. Lopez M, Varela L, Vazquez MJ, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16: 1001-8.
185. Remmers F, Delemarre-van de Waal HA. Developmental programming of energy balance and its hypothalamic regulation. Endocr Rev 2011; 32: 272-311.
186. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996; 98: 1101-6.
187. Konner AC, Klockener T, Bruning JC. Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond. Physiol Behav 2009; 97: 632-8.
188. Sainsbury A, Zhang L. Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit. Mol Cell Endocrinol 2010; 316: 109-19.
189. Lim CT, Kola B, Korbonits M. The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord 2011; 12: 173-86.
190. Begriche K, Sutton GM, Butler AA. Homeostastic and nonhomeostatic functions of melanocortin-3 receptors in the control of energy balance and metabolism. Physiol Behav 2011; 104: 546-54.
191. Sainsbury A, Zhang L. Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit. Obes Rev 2012; 13: 234-57.
192. Lopez M, Lage R, Saha AK, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 2008; 7: 389-99.
193. Gao S, Kinzig KP, Aja S, et al. Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci U S A 2007; 104: 17358-63.
194. McNay DE, Briancon N, Kokoeva MV, Maratos-Flier E, Flier JS. Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice. J Clin Invest 2012; 122: 142-52.
195. Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in the rat brain. Science 1983; 221: 877-9.
196. Funahashi H, Takenoya F, Guan JL, Kageyama H, Yada T, Shioda S. Hypothalamic neuronal networks and feedingrelated peptides involved in the regulation of feeding. Anat Sci Int 2003; 78: 123-38.
197. Lage R, Vazquez MJ, Varela L, et al. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J 2010; 24: 2670-9.
198. Xue B, Kahn BB. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 2006; 574: 73-83.
199. Pulinilkunnil T, He H, Kong D, et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 2011; 286: 8798-809.
200. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
201. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008; 14: 539-49.
202. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-62.
203. Hardie DG, Carling D, Gamblin SJ. AMP-activated protein kinase: also regulated by ADP? Trends Biochem Sci 2011; 36: 470-7.
204. Carling D, Mayer FV, Sanders MJ, Gamblin SJ. AMPactivated protein kinase: nature's energy sensor. Nat Chem Biol 2011; 7: 512-8.
205. Xiao B, Sanders MJ, Underwood E, et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011; 472: 230-3.
206. Cota D, Proulx K, Seeley RJ. The role of CNS fuel sensing in energy and glucose regulation. Gastroenterology 2007; 132: 2158-68.
207. Cota D, Matter EK, Woods SC, Seeley RJ. The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 2008; 28: 7202-8.
208. Proulx K, Cota D, Woods SC, Seeley RJ. Fatty acid synthase inhibitors modulate energy balance via mammalian target of rapamycin complex 1 signaling in the central nervous system. Diabetes 2008; 57: 3231-8.
209. Woods SC, Seeley RJ, Cota D. Regulation of food intake through hypothalamic signaling networks involving mTOR. Annu Rev Nutr 2008; 28: 295-311.
210. Villanueva EC, Munzberg H, Cota D, et al. Complex regulation of mammalian target of rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status. Endocrinology 2009; 150: 4541-51.
211. Blouet C, Ono H, Schwartz GJ. Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab 2008; 8: 459-67.
212. Townsend KL, Suzuki R, Huang TL, et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J 2012; 26: 2187-96.
213. Inhoff T, Stengel A, Peter L, et al. Novel insight in distribution of nesfatin-1 and phospho-mTOR in the arcuate nucleus of the hypothalamus of rats. Peptides 2010; 31: 257-62.
214. Cao R, Li A, Cho HY, Lee B, Obrietan K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci 2010; 30: 6302-14.
215. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271-2.
216. Hurtado-Carneiro V, Sanz C, Roncero I, Vazquez P, Blazquez E, Alvarez E. Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour. Mol Neurobiol 2012; 45: 348-61.
217. Yang SB, Tien AC, Boddupalli G, Xu AW, Jan YN, Jan LY. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012; 75: 425-36.
218. Kim JG, Horvath TL. mTOR signaling fades POMC neurons during aging. Neuron 2012; 75: 356-7.
219. Ono H, Pocai A, Wang Y, et al. Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats. J Clin Invest 2008; 118: 2959-68.
220. Reed AS, Unger EK, Olofsson LE, Piper ML, Myers MG, Jr., Xu AW. Functional role of suppressor of cytokine signaling 3 upregulation in hypothalamic leptin resistance and long-term energy homeostasis. Diabetes 2010; 59: 894-906.
221. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998; 395: 535-47.
222. Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003; 964: 107-15.
223. Fulton S, Pissios P, Manchon RP, et al. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 2006; 51: 811-22.
224. Hommel JD, Trinko R, Sears RM, et al. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 2006; 51: 801-10.
225. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325-8.
226. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
227. Sangiao-Alvarellos S, Varela L, Vazquez MJ, et al. Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. J Neuroendocrinol 2010; 22: 543-56.
228. Wortley KE, Chang GQ, Davydova Z, Fried SK, Leibowitz SF. Cocaine-and amphetamine-regulated transcript in the arcuate nucleus stimulates lipid metabolism to control body fat accrual on a high-fat diet. Regul Pept 2004; 117: 89-99.
229. Cannon B, Nedergaard J. Thyroid hormones: igniting brown fat via the brain. Nat Med 2010; 16: 965-7.
230. Ueno N, Oh-ishi S, Segawa M, et al. Effect of age on brown adipose tissue activity in the obese (ob/ob) mouse. Mech Ageing Dev 1998; 100: 67-76.
231. Hansen KR, Krasnow SM, Nolan MA, et al. Activation of the sympathetic nervous system by galanin-like peptide--a possible link between leptin and metabolism. Endocrinology 2003; 144: 4709-17.
232. Becerril S, Rodriguez A, Catalan V, et al. Transcriptional analysis of brown adipose tissue in leptin-deficient mice lacking inducible nitric oxide synthase evidences the role of Med1 in energy balance. Physiol Genomics 2012; 44: 678-88.
233. Pimentel GD, Dornellas AP, Rosa JC, et al. High-fat diets rich in soy or fish oil distinctly alter hypothalamic insulin signaling in rats. J Nutr Biochem 2012; 23: 822-8.
234. Mayer CM, Belsham DD. Central insulin signaling is attenuated by long-term insulin exposure via insulin receptor substrate-1 serine phosphorylation, proteasomal degradation, and lysosomal insulin receptor degradation. Endocrinology 2010; 151: 75-84.
235. Chai B, Li JY, Zhang W, Wu X, Zhang C, Mulholland MW. Melanocortin-4 receptor activation promotes insulinstimulated mTOR signaling. Peptides 2010; 31: 1888-93.
236. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Clinical endocrinology and metabolism. Regulation of energy homeostasis by peripheral signals. Best Pract Res Clin Endocrinol Metab 2004; 18: 497-515.
237. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005; 128: 175-91.
238. Ryan KK, Woods SC, Seeley RJ. Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab 2012; 15: 137-49.
239. Begg DP, Woods SC. The central insulin system and energy balance. Handbook of Experimental Pharmacology. Springer-Verlag Berlin Heidelberg 2012; Vol. 209: pp. 111-29.
240. Solon CS, Franci D, Ignacio-Souza LM, et al. Taurine enhances the anorexigenic effects of insulin in the hypothalamus of rats. Amino Acids 2012; 42: 2403-10.
241. Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 2001; 98: 4652-7.
242. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
243. Tseng YH, Kokkotou E, Schulz TJ, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008; 454: 1000-4.
244. Schulz TJ, Huang TL, Tran TT, et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. Proc Natl Acad Sci U S A 2011; 108: 143-8.
245. Whittle AJ, Lopez M, Vidal-Puig A. Using brown adipose tissue to treat obesity -the central issue. Trends Mol Med 2011; 17: 405-11.
246. Macotela Y, Emanuelli B, Mori MA, et al. Intrinsic differences in adipocyte precursor cells from different white fat depots. Diabetes 2012; 61: 1691-9.
247. Roa J, Tena-Sempere M. Energy balance and puberty onset: emerging role of central mTOR signaling. Trends Endocrinol Metab 2010; 21: 519-28.
248. Fernandez-Fernandez R, Martini AC, Navarro VM, et al. Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 2006; 254-255: 127-32.
249. Watanobe H, Habu S. Leptin regulates growth hormonereleasing factor, somatostatin, and alpha-melanocytestimulating hormone but not neuropeptide Y release in rat hypothalamus in vivo: relation with growth hormone secretion. J Neurosci 2002; 22: 6265-71.
250. Roa J, Garcia-Galiano D, Castellano JM, Gaytan F, Pinilla L, Tena-Sempere M. Metabolic control of puberty onset: new players, new mechanisms. Mol Cell Endocrinol 2010; 324: 87-94.
251. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349: 1614-27.
252. de RN, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 100: 10972-6.
253. Roa J, Aguilar E, Dieguez C, Pinilla L, Tena-Sempere M. New frontiers in kisspeptin/GPR54 physiology as fundamental gatekeepers of reproductive function. Front Neuroendocrinol 2008; 29: 48-69.
254. Quennell JH, Mulligan AC, Tups A, et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. Endocrinology 2009; 150: 2805-12.
255. Donato J, Jr, Cravo RM, Frazao R, et al. Leptin's effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons. J Clin Invest 2011; 121: 355-68.
256. Louis GW, Greenwald-Yarnell M, Phillips R, Coolen LM, Lehman MN, Myers MG, Jr. Molecular mapping of the neural pathways linking leptin to the neuroendocrine reproductive axis. Endocrinology 2011; 152: 2302-10.
257. Donato J, Jr, Silva RJ, Sita LV, et al. The ventral premammillary nucleus links fasting-induced changes in leptin levels and coordinated luteinizing hormone secretion. J Neurosci 2009; 29: 5240-50.
258. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMPactivated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002; 277: 23977-80.
259. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945-57.
260. Risson V, Mazelin L, Roceri M, et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol 2009; 187: 859-74.
261. Veilleux A, Houde VP, Bellmann K, Marette A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulininduced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 2010; 24: 766-78.
262. Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 2012; 23: 226-34.
263. Zhang H, Zhang G, Gonzalez FJ, Park SM, Cai D. Hypoxiainducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol 2011; 9: e1001112.
264. Chen H, Simar D, Ting JH, Erkelens JR, Morris MJ. Leucine improves glucose and lipid status in offspring from obese dams, dependent on diet type, but not caloric intake. J Neuroendocrinol 2012; 24: 1356-64.
265. Rovira J, Marcelo AE, Burke JT, et al. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int 2008; 21: 992-8.
266. Chang GR, Chiu YS, Wu YY, et al. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci 2009; 109: 496-503.
267. Chang GR, Wu YY, Chiu YS, et al. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin Pharmacol Toxicol 2009; 105: 188-98.
268. Houde VP, Brule S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59: 1338-48.
269. Kimura N, Tokunaga C, Dalal S, et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003; 8: 65-79.
270. Canabal DD, Potian JG, Duran RG, McArdle JJ, Routh VH. Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol 2007; 293: R592-R600.
271. Potier M, Darcel N, Tome D. Protein, amino acids and the control of food intake. Curr Opin Clin Nutr Metab Care 2009; 12: 54-8.
272. Warden SM, Richardson C, O'Donnell J, Jr., Stapleton D, Kemp BE, Witters LA. Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem J 2001; 354: 275-83.
273. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMPactivated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006; 290: H2472-H2479.
274. Hurley RL, Barre LK, Wood SD, et al. Regulation of AMPactivated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 2006; 281: 36662-72.
275. Horman S, Vertommen D, Heath R, et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 2006; 281: 5335-40.
276. Djouder N, Tuerk RD, Suter M, et al. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J 2010; 29: 469-81.
277. Dagon Y, Hur E, Zheng B, Wellenstein K, Cantley LC, Kahn BB. p70S6 Kinase Phosphorylates AMPK on Serine 491 to Mediate Leptin's Effect on Food Intake. Cell Metab 2012; 16: 104-12.